Leachable compounds from sample tubes don't just contaminate specimens—they can silently corrupt your immunoassay results. These chemical substances, such as plasticizers from tube walls or additives from rubber stoppers, leach into blood samples during storage and directly interfere with solid-phase immunoassays. They do this by displacing protein-bound analytes, physically stripping capture antibodies from the solid phase, blocking critical binding sites, or inhibiting the signal-generating enzymes. The result is a cascade of false signals that can mimic or mask the true concentration of an analyte.
The interaction between leachable compounds and immunoassay components is compound-specific and can skew results in ways that are difficult to detect without proper validation. Understanding the four core mechanisms—antibody desorption, enzyme inhibition, binding site blockade, and analyte displacement—is the foundation for selecting low-extractable collection materials and engineering robust assay buffers.
How Leachables Hijack the Immunoassay Reaction
The interference isn't random. Leachables exploit the very design principles of solid-phase immunoassays: surface-bound capture reagents, enzyme-dependent signaling, and equilibrium-based analyte binding.
Displacement of Protein-Bound Analytes
Many plasticizers and hydrophobic additives compete with serum proteins for lipophilic drugs or hormones. When these leachables enter the specimen, they can strip the analyte from its natural protein carrier, artificially increasing the free, unbound fraction that an immunoassay detects. This is especially misleading in therapeutic drug monitoring, where only free drug is pharmacologically active.
Physical Stripping of Immobilized Capture Antibodies
This is one of the most catastrophic interference mechanisms. Organosilicone surfactants from serum separator tubes and certain plasticizers can directly desorb capture antibodies from the solid phase—be it a coated microplate well or a bead. In a competitive assay, this loss of immobilized antibody reduces the available binding sites, causing less labeled conjugate to be bound and falsely signaling an elevated analyte level.
Blocking of Antigen–Antibody Binding Sites
Even without ripping off the capture layer, some leachables act like molecular glue. They non-specifically adsorb to the solid surface or to the antibody itself, sterically blocking the paratope or the antigen’s epitope. This reduces specific signal generation, mimicking low analyte concentrations where none exist.
Direct Inhibition of the Signal-Generating Enzyme
The final blow often happens during detection. Plasticizers like tris(2-butoxyethyl) phosphate can inhibit the activity of horseradish peroxidase or alkaline phosphatase, the workhorse enzymes behind colorimetric or chemiluminescent readouts. A slower or weaker enzymatic reaction translates directly to a lower signal, which is then misread as a lower analyte concentration.
The Usual Suspects: Where Leachables Come From
Not all collection tubes are created equal. The interference profile is determined by the material composition of the tube and its stopper.
- Low-grade rubber stoppers release a cocktail of additives, including vulcanization accelerators and plasticizers, that are notorious for hydrophobic interference.
- Plastic tubes made with cheap plasticizers can leach compounds like tris(2-butoxyethyl) phosphate, which interact both with the solid phase and the enzyme conjugate.
- Serum separator tubes often contain organosilicone surfactants to improve gel barrier integrity, but these surfactants can migrate into the serum and become potent antibody strippers.
Understanding the Trade-offs
Eliminating one interference source can introduce another. This is the hidden cost of chasing absolute inertness in sample collection.
The Cost of Ultra-Low-Extractable Materials
Specifying tubes with medical-grade, high-purity polymers and specially formulated stoppers raises manufacturing costs. For diagnostic kit manufacturers, passing that cost to the end user may limit adoption in price-sensitive markets. The challenge is to find the threshold where the clinical benefit of avoiding interference outweighs the economic penalty.
Overcompensating with Assay Diluents
Designing assay diluents that neutralize hydrophobic matrix interference—for example, by adding high levels of blocking proteins or surfactants—can dampen specific signal if formulation is too aggressive. You risk exchanging one problem (leachable interference) for another (reduced assay sensitivity or hook effects in sandwich assays). The diluent must be precisely tuned to quench leachables without disrupting the antibody-antigen equilibrium.
Making the Right Choice for Your Goal
The true solution is not a single tube or a single buffer, but a systematic pre-validation strategy that treats the collection device as an integral part of the assay system.
- If your primary focus is assay development: Evaluate each raw material's stability against known tube leachables during early optimization. Screen capture antibody formulations for resistance to desorption by organosilicone surfactants and plasticizers.
- If your primary focus is clinical laboratory operations: Adopt a closed-system approach—validate your immunoassay's performance with the exact tube type and lot you will use. Never assume a generic "serum tube" will behave identically.
- If your primary focus is quality management in IVD manufacturing: Perform forced-extraction studies on every incoming lot of collection tubes and stoppers, then test those extracts in the final assay to set lot-release criteria.
By treating the collection tube as an extension of the assay buffer, you ensure that what leaves the needle is chemically identical to what the antibody sees.
Summary Table:
| Interference Mechanism | Primary Sources & Leachables | Direct Impact on Assay | Key Mitigation Approach |
|---|---|---|---|
| Analyte Displacement | Plasticizers, hydrophobic additives | Strips analytes from serum carriers, artificially inflating free fraction results | Optimize assay diluent binding capacity |
| Antibody Desorption | Organosilicone surfactants, plasticizers | Physically strips capture antibodies from solid phase, skewing signal | Use high-purity polymers & screen capture antibodies |
| Binding Site Blockade | Low-grade rubber additives, surfactants | Sterically blocks antibody paratopes or antigen epitopes, reducing signal | Fine-tune protective blocking proteins in buffer |
| Enzyme Inhibition | Tris(2-butoxyethyl) phosphate (TBEP) | Inhibits HRP/ALP enzyme activity, leading to falsely lowered concentrations | Perform forced-extraction testing on tube lots |
Overcome Immunoassay Interference with Pure Raw Materials & Expert Solutions
Don't let sample collection leachables compromise your assay accuracy or clinical validation. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.
Whether you need ultra-pure assay components, customized diluent formulations, or comprehensive raw material screening to prevent leachable interference, our technical experts are ready to assist.
Contact CamelBio today to optimize your assay performance and ensure reproducible results.